Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
May 30, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
May 28, 2014
SPI-2012, is a Long-Acting GCSF that utilizes a proprietary platform technology, LAPSCOVERY™, designed to the maximize pharmacological activity of GCSF with potential advantages relating to more rapid and potent granulocyte recovery compared to pegylated filgrastim.
May 09, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
May 08, 2014
Total product sales for the three months ended March 31, 2014 were $40.1 million , compared to $29.3 million in the same period last year, an increase of 37%. Non-GAAP EPS was $0.01 , and GAAP EPS was ( $0.44 ). Spectrum expects a decision on the NDA approval of Beleodaq™ by the FDA's decision date
May 01, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Apr 23, 2014
CE Melphalan is being developed as a novel version of the well-established conditioning treatment in autologous transplant for patients with multiple myeloma. CE Melphalan does not contain propylene glycol, an ingredient in currently available products which has been associated with renal and
Apr 21, 2014
Joseph Turgeon has more than 30 years of experience in the biotech industry, including 22 years at Amgen; until recently was Spectrum's Chief Commercial Officer Thomas Riga promoted to Senior Vice President and Chief Commercial Officer; Tom has more than 15 years' experience in the biotech
Mar 07, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Mar 06, 2014
Total revenues for the year ended December 31, 2013 were $155.9 million . Total revenues for the three months ended December 31, 2013 were $41.5 million . Q4 Non-GAAP diluted EPS was $0.05 , and GAAP basic and diluted EPS was ( $0.63 ); the difference is primarily due to non-cash charges.
Feb 27, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Feb 06, 2014
FDA grants Priority Review Designation FDA decision date based on PDUFA set for August 9, 2014 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology
Jan 09, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Dec 18, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced today the pricing of its offering of $100 million aggregate principal amount of 2.75% convertible senior notes due 2018 (the "Convertible Notes"). The Convertible Notes will be offered and sold in a
Dec 16, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced today that it intends, subject to market and other conditions, to offer $100 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes").
Dec 11, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced encouraging clinical data from investigator-sponsored studies of
Dec 10, 2013
Filed for Accelerated Approval with a request for Priority Review. Response from the FDA regarding acceptance to file is expected within 60 days from the FDA receipt date. Over 1,000 patients have been exposed to belinostat across the development program that included 14 Sponsor-initiated studies
Dec 06, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 55th
Nov 12, 2013
Total revenues for the three months ended September 30, 2013 were $42.4 million as compared to $33.2 million the previous quarter. Non-GAAP EPS was $0.02 , and GAAP EPS was ( $0.13 ). Marqibo ® (vinCRIStine sulfate LIPOSOME injection) successfully launched in September.
Nov 11, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Nov 08, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Displaying 161 - 180 of 784